<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Neoadjuvant chemotherapy is increasingly becoming the first treatment step in breast cancer. Despite the enormous advantages of this therapy, it is a method characterized by a high level of toxicity and thus carries a huge burden for the patient. Therefore, it is highly desirable to begin monitoring the patient’s response to treatment at an earlier stage. Currently, apart from traditional imaging methods, a completely new technique (in the context of monitoring the outcomes of chemotherapy), called quantitative ultrasound, is gaining popularity. It is a method based on the exact same ultrasound echoes as in traditional ultrasound imaging. The innovative approach of the method is that these echoes are not used for visualization but to characterize the condition of the tissue by parameterizing it with the aid of ultrasound biomarkers. The biomarkers make it possible to assess the state of the tissue at the microscopic level, and thus evaluate changes occurring in the tissue under the influence of treatment at a very early treatment stage. The present paper aims to familiarize the reader with the physical foundations of this method as well as present the latest results of related research.</p></abstract>

Neoadjuvant chemotherapy is increasingly becoming the first treatment step in breast cancer. Despite the enormous advantages of this therapy, it is a method characterized by a high level of toxicity and thus carries a huge burden for the patient. Therefore, it is highly desirable to begin monitoring the patient’s response to treatment at an earlier stage. Currently, apart from traditional imaging methods, a completely new technique (in the context of monitoring the outcomes of chemotherapy), called quantitative ultrasound, is gaining popularity. It is a method based on the exact same ultrasound echoes as in traditional ultrasound imaging. The innovative approach of the method is that these echoes are not used for visualization but to characterize the condition of the tissue by parameterizing it with the aid of ultrasound biomarkers. The biomarkers make it possible to assess the state of the tissue at the microscopic level, and thus evaluate changes occurring in the tissue under the influence of treatment at a very early treatment stage. The present paper aims to familiarize the reader with the physical foundations of this method as well as present the latest results of related research.

Quantitative ultrasonography as a tool for the evaluation of breast tumor response to neoadjuvant chemotherapy

Journal of Ultrasonography

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Neoadjuvant chemotherapy is increasingly becoming the first treatment step in breast cancer. Despite the enormous advantages of this therapy, it is a method...

Quantitative ultrasonography as a tool for the evaluation of breast tumor response to neoadjuvant chemotherapy

Article Category: Review paper

Publié en ligne: 27 avr. 2022

Pages: 86 - 92

Reçu: 11 nov. 2021

Accepté: 25 janv. 2022

DOI: https://doi.org/10.15557/JoU.2022.0015

Mots clés
quantitative ultrasound, breast cancer, neoadjuvant chemotherapy

© 2022 Hanna Piotrzkowska-Wróblewska, Katarzyna Dobruch-Sobczak, Jerzy Litniewski, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Quantitative ultrasonography as a tool for the evaluation of breast tumor response to neoadjuvant chemotherapy

Article Category: Review paper

Publié en ligne: 27 avr. 2022

Pages: 86 - 92

Reçu: 11 nov. 2021

Accepté: 25 janv. 2022

DOI: https://doi.org/10.15557/JoU.2022.0015

Mots clésquantitative ultrasound, breast cancer, neoadjuvant chemotherapy

© 2022 Hanna Piotrzkowska-Wróblewska, Katarzyna Dobruch-Sobczak, Jerzy Litniewski, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
quantitative ultrasound, breast cancer, neoadjuvant chemotherapy